| [1] |
CHEN W, ZHENG R, BAADE PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115-132. DOI: 10.3322/caac.21338. |
| [2] |
GORDAN JD, KENNEDY EB, ABOU-ALFA GK, et al. Systemic therapy for advanced hepatocellular carcinoma: ASCO guideline[J]. J Clin Oncol, 2020, 38(36): 4317-4345. DOI: 10.1200/JCO.20.02672. |
| [3] |
Bureau of Medical AdministrationNational Health Commission of the People's Republic of China. Guidelines for diagnosis and treatment of primary liver cancer in China (2019 edition)[J]. J Clin Hepatol, 2020, 36(2): 277-292. DOI: 10.3969/j.issn.1001-5256.2020.02.007. |
| [4] |
ZHOU J, YU L, GAO X, et al. Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma[J]. J Clin Oncol, 2011, 29(36): 4781-4788. DOI: 10.1200/JCO.2011.38.2697. |
| [5] |
SUN YF, XU Y, YANG XR, et al. Circulating stem cell-like epithelial cell adhesion molecule-positive tumor cells indicate poor prognosis of hepatocellular carcinoma after curative resection[J]. Hepatology, 2013, 57(4): 1458-1468. DOI: 10.1002/hep.26151. |
| [6] |
QU C, WANG Y, WANG P, et al. Detection of early-stage hepatocellular carcinoma in asymptomatic HBsAg-seropositive individuals by liquid biopsy[J]. Proc Natl Acad Sci U S A, 2019, 116(13): 6308-6312. DOI: 10.1073/pnas.1819799116. |
| [7] |
Guidelines Working Committee of Chinese Society of Clinical Oncology. Guidelines for the diagnosis and treatment of primary liver cancer (2020 edition)[M]. Beijing: People's Medical Publishing House, 2020.
中国临床肿瘤学会指南工作委员会. 原发性肝癌诊疗指南2020[M]. 北京: 人民卫生出版社, 2020.
|
| [8] |
BI F, QIN S, GU S, et al. Donafenib versus sorafenib as first-line therapy in advanced hepatocellular carcinoma: An open-label, randomized, multicentre phase Ⅱ/Ⅲ trial[C]. Chicago, 2020 ASCO Annual Meeting Symposium: abstract 4506.
|
| [9] |
YUAN GS, HE WM, HU XY, et al. Clinical efficacy and safety analysis of camrelizumab combined with apatinib as a second-line therapy for unresectable hepatocellular carcinoma: A multicenter retrospective study[J]. Chin J Hepatol, 2021, 29(4): 326-331. DOI: 10.3760/cma.j.cn501113-20210329-00148. |
| [10] |
European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma[J]. J Hepatol, 2018, 69(1): 182-236. DOI: 10.1016/j.jhep.2018.03.019. |
| [11] |
CALLEJA JL, CRESPO J, RINCÓN D, et al. Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort[J]. J Hepatol, 2017, 66(6): 1138-1148. DOI: 10.1016/j.jhep.2017.01.028. |
| [12] |
MARRERO JA, KULIK LM, SIRLIN CB, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases[J]. Hepatology, 2018, 68(2): 723-750. DOI: 10.1002/hep.29913. |
| [13] |
TANG A, BASHIR MR, CORWIN MT, et al. Evidence supporting LI-RADS major features for CT-and MR imaging-based diagnosis of hepatocellular carcinoma: A systematic review[J]. Radiology, 2018, 286(1): 29-48. DOI: 10.1148/radiol.2017170554. |
DownLoad: